Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
PepGen Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
10/12/2023 8-K Quarterly results
08/08/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
08/08/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"At-The-Market Equity Offering Sales Agreement by and between the Company and Stifel, Nicolaus & Company, Incorporated",
"Opinion of Goodwin Procter LLP"
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/08/2023 8-K Quarterly results
Docs: "Condensed Consolidated Statements of Operations Three Months EndedJune 30, 2023 2022 Operating expenses: Research and development $ 16,926 $ 14,240 General and administrative 4,218 3,401 Total operating expenses $ 21,144 $ 17,641 Operating loss $ $ Other income Interest income 1,684 250 Other income , net 76 Total other income , net 1,622 326 Net loss before income tax $ $ Income tax expense - - Net loss $ $ Net loss per share, basic and diluted $ $ Weighted-average common shares outstanding, basic and diluted 23,790,430 14,090,455 Condensed Consolidated Balance Sheets June 30,2023"
06/02/2023 144 Form 144 - Report of proposed sale of securities:
05/18/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Investor Contact"
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/11/2023 8-K Quarterly results
Docs: "Condensed Consolidated Statements of Operations Three Months EndedMarch 31, 2023 2022 Operating expenses: Research and development $ 14,360 $ 10,707 General and administrative 3,671 3,186 Total operating expenses $ 18,031 $ 13,893 Operating loss $ $ Other income Interest income $ 1,792 $ 9 Other income , net 58 Total other income , net $ 1,712 $ 67 Net loss before income tax $ $ Income tax expense — Net loss $ $ Net loss per share, basic and diluted $ $ Weighted-average common shares outstanding, basic and diluted 23,761,915 963,588 Condensed Consolidated Balance Sheets March 31,2023"
03/27/2023 8-K Quarterly results
03/23/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/23/2023 10-K Annual Report for the period ended December 31, 2022
03/23/2023 8-K Quarterly results
Docs: "Condensed Consolidated Statements of Operations Twelve Months Ended December 31, Three Months Ended December 31, 2022 2021 2022 2021 Operating expenses: Research and development $ 54,077 $ 18,999 $ 13,166 $ 4,541 General and administrative 14,224 8,110 4,047 2,670 Total operating expenses $ 68,301 $ 27,109 $ 17,213 $ 7,211 Operating loss $ $ $ $ Other income Interest income 2,793 — 1,591 — Other income , net 110 67 Total other income , net 2,903 1,563 67 Net loss before income tax $ $ $ $ Income tax expense — 714 — Net loss $ $ $ $ Condensed Consolidated Balance Sheets December 31, 2022 December 31, 2021 Assets Current assets: Cash and cash equivalents $ 181,752 $ 132,895 Other receivables 58 4,744 Prepaid expenses and other current assets 4,273 2,347 Total current assets $ 186,083 $ 139,..."
03/22/2023 8-K Quarterly results
02/14/2023 SC 13G/A VIKING GLOBAL INVESTORS LP reports a 6.5% stake in PepGen Inc.
02/10/2023 SC 13G/A FMR LLC reports a 10.9% stake in PEPGEN INC
02/09/2023 SC 13G FMR LLC reports a 9.3% stake in PEPGEN INC
01/17/2023 SC 13G/A Qatar Investment Authority reports a 5.3% stake in PEPGEN INC.
12/07/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Investor Contact Laurence Watts Gilmartin Group"
09/28/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Investor Contact Laurence Watts Gilmartin Group [email protected]",
"PHASE 1 TRIAL OF PGN-EDO51 FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY"
09/22/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Investor Contact Laurence Watts Gilmartin Group [email protected]"
07/22/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "SCIENTIFIC ADVISORY BOARD MEMBER AGREEMENT This Scientific Advisory Board Member Agreement, effective 1st August, 2022 , is between PepGen Inc., a Delaware corporation, and Caroline Godfrey, an individual residing at the address set forth on the signature page hereto . In light of Advisor's expertise in areas consistent with Company's research and development, business and product strategy, Company and Advisor agree as follows: 1. Services. Advisor agrees to contribute to Company's success by attending informal and formal meetings of the Company’s Scientific Advisory Board and to provide such consulting, advisory and related services to and for the Company from time to time, at Company's request . Services may be rendered in person, or by telephone, electronic mail or other means. While th..."
06/23/2022 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
06/16/2022 10-Q Quarterly Report for the period ended March 31, 2022
06/16/2022 8-K Quarterly results
Docs: "Condensed Consolidated Statements of Operations Three Months Ended March 31, 2022 2021 Operating expenses: Research and development $ 10,707 $ 5,530 General and administrative 3,186 1,098 Total operating expenses $ 13,893 $ 6,628 Operating loss $ $ Other income Interest income 9 — Other income , net 58 Total other income , net 67 Net loss before income tax $ $ Income tax expense — Net loss $ $ Net loss per share, basic and diluted $ $ Weighted-average common shares outstanding, basic and diluted 963,588 894,060 Condensed Consolidated Balance Sheets March 31, 2022 December 31, 2021 Assets Current assets: Cash and cash equivalents $ 118,854 $ 132,895 Other receivables 4,574 4,744 Prepaid expenses and other current assets 2,240 2,347 Total current assets $ 125,668 $ 139,986 Property and equip..."
05/20/2022 SC 13D Form SC 13D - General statement of acquisition of beneficial ownership:
05/20/2022 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
05/17/2022 SEC STAFF LETTER Form SEC STAFF LETTER - SEC Staff Letter: REDACTED EXHIBIT
05/13/2022 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
05/12/2022 EFFECT Form EFFECT - Notice of Effectiveness:
05/10/2022 SC 13G Flynn James E reports a 4.3% stake in PepGen Inc.
05/10/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
05/10/2022 POS AM Form POS AM - Post-Effective amendments for registration statement:
05/09/2022 424B4 Form 424B4 - Prospectus [Rule 424(b)(4)]:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy